Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

miconazole vaginal (Rx, OTC)Brand and Other Names:Monistat-1 Combination Pack, Monistat-3 Combination Pack, more...Monistat-7 Combination Pack, Monistat-7 Vaginal Cream, Monistat-7 Vaginal Suppositories, Vagistat-3 Combination Pack, Femizol M

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

vaginal cream

  • 2%
  • 4%

vaginal suppository

  • 100mg
  • 200mg
more...

Vulvovaginal Candidiasis

Vaginal 2% cream qHS x7 day

100 mg vaginal suppository qHS x7 day

200 mg vaginal suppository qHS x3 day

Dosage Forms & Strengths

vaginal cream

  • 2%
  • 4%

vaginal suppository

  • 100mg
  • 200mg
more...

Vulvovaginal Candidiasis

Infants and children: Not indicated

Adolescents

  • As adults
  • Vaginal 2% cream qHS x7 days
  • 100 mg vaginal suppository qHS x7 days
  • 200 mg vaginal suppository qHS x3 days
Next

Interactions

Interaction Checker

miconazole vaginal and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Allergic contact dermatitis

            Burning

            Irritation

            Itching

            Maceration

            Previous
            Next

            Warnings

            Contraindications

            Pregnancy: 1st trimester

            Known hypersensitivity to drug

            Cautions

            Hypersensitivity to other azoles

            IV form not commercially available

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: unknown

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Distribution: widely to body tissues; penetrates well into inflamed joints, vitreous humor of eye, & peritoneal cavity, but poorly into saliva & sputum; crosses blood-brain barrier but only to a small extent Protein Bound: 91-93% Half-life elimination: multiphasic: initial: 40 min; secondary: 126 min; terminal: 24 hr

            Metabolism: hepatic P450 CYP3A4

            Excretion

            Feces: ~50%

            Urine: <1% as unchanged drug)

            Mechanism of Action

            Interferes with mitochondrial & peroxisomal enzymes

            Alters cell membrane permeability

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.